Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab for adults with chronic pruritus of unknown origin
CTR20220920Phase 3Active
- Sponsor
- Sanofi
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of dupilumab in chronic idiopathic pruritus, sponsored by Sanofi. Started Aug 2022; status: active.
02
Drugs
03
Conditions
chronic idiopathic pruritus
Beyond the preview
Go deeper on CTR20220920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220920.